PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 244 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR An integral part of research September 21, 2022 Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... June 26, 2021 Addressing Cancer Pain with Complementary Methods (Part 2) April 10, 2023 New option to treat advanced oesophageal cancer approved for NHS in... August 11, 2021 Load more HOT NEWS Breast Cancer Survivors in Happy Romantic Relationships Are Healthier, Study Says How Exercise Can Help You Cope With the Mental and Emotional... Helping Kids with Cancer Speak for the Supportive Care They Need Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic...
